Citigroup Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $59.00

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price decreased by Citigroup to $59.00 in a research note released on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. Wall Street Zen downgraded Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Guggenheim dropped their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, HC Wainwright cut their price objective on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.40.

Olema Pharmaceuticals Trading Up 0.7%

Shares of Olema Pharmaceuticals stock opened at $10.51 on Tuesday. Olema Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $36.26. The stock has a market cap of $919.62 million, a P/E ratio of -4.96 and a beta of 2.03. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $11.24 and its 200-day moving average is $15.44.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). Equities research analysts predict that Olema Pharmaceuticals will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 12.56% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OLMA. Bain Capital Life Sciences Investors LLC raised its stake in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in Olema Pharmaceuticals by 11.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after buying an additional 750,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in Olema Pharmaceuticals by 5.9% during the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after buying an additional 398,294 shares in the last quarter. BlackRock Inc. bought a new position in Olema Pharmaceuticals in the 2nd quarter valued at about $84,001,000. Finally, Siren L.L.C. increased its holdings in Olema Pharmaceuticals by 44.1% in the 1st quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock valued at $70,926,000 after buying an additional 1,456,249 shares during the period. Institutional investors own 91.78% of the company’s stock.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Analyst support remains strong: Piper Sandler reaffirmed its Buy rating, while Goldman Sachs also assigned a Buy rating to Olema Pharmaceuticals. Continued bullish coverage may help offset concerns about the company’s ongoing losses. Piper Sandler Reaffirms Buy Rating Goldman Sachs Buy Rating
• Positive Sentiment: New CFO appointed: Olema appointed Jason O’Byrne as chief financial officer. The leadership addition could strengthen financial planning and investor communications as the company funds its development pipeline. Olema Appoints Jason O’Byrne CFO
• Neutral Sentiment: JPMorgan remains constructive but reduced its target: The firm cut its price target from $52 to $46 while maintaining an Overweight rating. The target still implies substantial potential upside, but the reduction signals more cautious near-term expectations. JPMorgan Price Target Update
• Negative Sentiment: Weak earnings hurt sentiment: Olema’s latest quarterly loss of $0.61 per share missed the $0.55 consensus estimate, contributing to reports that the shares gapped lower following the results. Olema Shares Gap Down Following Weak Earnings
• Negative Sentiment: HC Wainwright reduced forecasts across 2026–2030: The analyst lowered EPS estimates for every listed period, including 2026 to a loss of $2.44 per share from $2.24. Although it retained a Buy rating and $36 target, deeper projected losses highlight continued spending and profitability risk.
• Negative Sentiment: Citigroup issued a pessimistic outlook: The negative forecast adds to pressure on OLMA and reinforces concerns about valuation, future losses and execution risk. Citigroup Pessimistic Forecast

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.